Issue link: https://www.e-digitaleditions.com/i/1517675
14 BioPharm International ® Quality and Regulatory Sourcebook eBook March 2024 www.biopharminternational.com Quality by Design Traditional risk assessment workflows using spread- sheets or word-processors can be laborious and have limited capacity to connect with the vast volumes of data generated by organizations, including product specific understanding. This leads to challenges with leveraging prior knowledge (3), which in turn can result in unwanted inconsistencies between risk assessments for a single product or across multiple products of the same modality. While these risk assessments are acknowledged for their inherent value, they are limited in scalability and suscep- tible to human errors. The resource-intensive nature of these assessments results in the generation of large data- sets that prove complex to maintain and analyze using traditional techniques, leading to knowledge silos. In response to the evolving landscape, pharmaceuti- cal companies have developed risk assessments embed- ded with prior knowledge, often stored in a collection of spreadsheets and written report templates. However, these encounter the same challenges that extend beyond their effectiveness, posing limitations on knowledge shar- ing. The current paradigm of risk assessments operating primarily in this traditional, siloed, unintegrated format results in significant challenges associated with collab- orative risk management across disciplines, groups, and even regulatory agencies, making the need for a more in- tegrated and collaborative digital approach evident. The implementation of digital tools (6), utilizing smart technologies such as robotics, artificial intelligence, auto- mation, and data analytics, is deemed essential to meet the growing demand for the accelerated delivery of medicines in an ever-changing global market (7,8). Digitalization of pharmaceutical systems, including QbD risk assess- ments, is positioned as a valuable strategy to address the challenges of drug substance and product development. By embracing the capabilities of smart technologies, the pharmaceutical industry can enhance QbD product and analytical procedure development as outlined in ICH Q2, Q8–12, and Q14 (9) leading to consistent implementation of these guidelines. A digital platform designed to facilitate risk assess- ments within a wider digital ecosystem (including digita- lization of other QbD and product development processes) holds the potential to expedite the overall drug develop- ment process and enable predictive analytics (Figure 1). This alignment not only highlights the positive outcomes associated with digital risk assessment platforms but also positions them as a strategic imperative in the contem- porary landscape of pharmaceutical development. One such digital QRM platform used to facilitate QbD risk as- sessments is iRISK (10), developed by Valgenesis Inc. This web-based tool has been employed by the authors for con- ducting QbD risk assessments and other QbD workflows supporting the development and manufacture of small molecules, biologics, and vaccines. It has proved valuable as a tool in enabling the development of robust drug sub- stance and drug product control strategies across multi- ple products. The use of iRISK has resulted in numerous benefits and the authors anticipate that this digital risk as- sessment platform will become an integral part of a much broader product development digital ecosystem. Drivers for QbD risk assessment digitalization A powerful digital risk assessment platform (a single QbD tool) can enhance data interoperability (establishing links between product, process, and analytical understanding), advanced analytics, and knowledge transfer, enabling FIGURE 1. High-level representation of quality-by-design (QbD) digitization goals and benefits. FIGURES COURTESY OF THE AUTHORS